ABION Inc (203400) Fair Value & Analysis
Healthcare · KR · Market cap 76.6B KRW
Fair value as of: Jul 7, 2026
From 1 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 4,952 KRW to 488.45 KRW (−90.1%) since Jun 24, 2026. Share price −61.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 711.00 KRW – 6,088 KRW · fair‑value band 322.37 KRW – 610.56 KRW · the 711.00 KRW price screens above the 488.45 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ABION Inc (203400) currently trades at 711.00 KRW, while our model-based Fair Value estimate is 488.45 KRW — implying the stock looks roughly 31.3% overvalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 1.0B KRW. Revenue grew 30.7% year over year. It earns a return on equity of -63.4%. Net debt stands at 13.9B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 322.37 KRW (bear case) to 610.56 KRW (bull case); at 711.00 KRW, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -31%, 203400 screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ABION Inc reported revenue of 880M KRW in FY2025 versus 1.6B KRW in FY2021, a compound −14.4%/yr. Reported net income was −29.1B KRW in FY2025.
Is 203400 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ABION Inc (203400) undervalued?
What is the fair value of 203400?
What is the quality score of 203400?
What is the revenue of ABION Inc (203400)?
What is the net profit margin of 203400?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.